Michael Reel, director of technical services at Alcami, and Quinn McGinnis, process engineer at Alcami, recently contributed to an article in Manufacturing Technology Insights titled Challenge Accepted! Problem-Solving Examples for Packaging Dilemmas. In the article, Reel and McGinnis discuss solutions to pharmaceutical packaging challenges through straightforward case studies.

Michael Freeman, associate director and business unit head for lab services at Alcami, recently contributed to an article in Drug Development & Delivery titled Outsourcing Analytical Testing: Novel Services Elicit Consistent, Quantifiable, & Faster Results. In the article, Freeman explains how Alcami's end-to-end analytical testing platform supports client programs through every stage of a product's lifecycle, from early phase development activities to commercial support for both small and large molecule products.

Mark Millar, director and business unit head for API at Alcami, recently participated in the high-potency APIs section of Speciality Chemicals Magazine. The write-up goes in-depth about investments being made in the high-potency API market and provides an overview into occupational health and safety challenges in manufacturing.

A Full-Time Equivalent (FTE) agreement is a comprehensive analytical service that grants pharmaceutical and biotech companies the flexibility, freedom, and consistent control of their outsourced laboratory programs. In this article, we will discuss the benefits of establishing a FTE program with an outsourcing partner and examine the customized solutions that are available for a broad spectrum of testing needs.

Alcami’s Extended Workbench offering is a FTE program tailored to your specific needs. An Extended Workbench program can vary in size, management approach, and scope, and is available across any pharmaceutical platform, from small molecule API to biologic drug product. 

Transaction Advances Alcami’s Strategic Plan by Adding Scale in Attractive and Growing Parenteral Markets

Alcami Investors Make Additional Equity Investment Alongside Ampersand Capital Partners to Fund Expansion

Durham, NC (USA) – January 17, 2020 – Alcami Corporation (“Alcami”), a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, today announced it has acquired TriPharm Services (“TriPharm”), a new state-of-the-art sterile fill-finish manufacturing center located near Research Triangle Park, North Carolina. The acquisition of TriPharm follows the recently announced $17 million expansion of Alcami’s sterile fill-finish facility in Charleston, South Carolina.

Next Step in Alcami’s Strategic Plan to Focus its Platform on High-Growth Market Segments

Durham, NC (USA) – January 8, 2020 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, today announced the sale of its preclinical and early stage active pharmaceutical ingredient (API) facility in Weert, Netherlands to MercachemSyncom, a leading mid-sized European integrated drug-discovery and development contract research organization. Terms were not disclosed. 

Name: Katie Shupe

Alcami Site: St. Louis, MO

What is your role? 
I am a lead chemistry analyst. I assist with training and scheduling, provide guidance in the lab, and perform routine testing. 

How long have you been with Alcami?
I have been with Alcami for almost three months. 

What is the most rewarding part of your job? 
The most rewarding part of my job is helping others, whether they be my fellow chemists in the lab, or patients, who are ultimately our end customers. 

Durham, NC (USA) – December 17, 2019 – Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, today announced plans to expand the company’s current operations in Charleston County. The $17 million investment is expected to create 30 new jobs.

Name: Norman Chieng, PhD

Alcami Site: Charleston, SC 

What is your role? 
I am a senior scientist in formulations and development. My role is to develop, formulate, and transfer the science and technology for the formulation and process into our cGMP manufacturing space. 

How long have you been with Alcami?
I have been with Alcami since March of 2019.

What is the most rewarding part of your job? 
The most rewarding part of my job is applying the fundamental science behind drug design. At Alcami, we are helping improve the quality of patients’ lives by taking a client’s product and developing a way to formulate and deliver it.

Alcami is featured among Wisconsin’s leading innovative global health and technology companies in a recent industry profile published by the Wisconsin Economic Development Corporation (WEDC). 

WEDC leads economic development efforts for the state by advancing and maximizing opportunities in Wisconsin for businesses, communities, and people to thrive in a globally competitive environment.